The problem is most nutraceutical products<\/a> \u2014 that is, dietary supplements used for medicinal purposes \u2014 are unproven. Peer-reviewed trials are rare for branded products, and when they exist, they are often underpowered, methodologically limited, or uninterpretable. The National Institutes of Health advises<\/a> consumers against assuming that supplements can reverse the course of disease.\u00a0<\/p>\n All of this leaves consumers and health experts wondering whether the absence of evidence is evidence of absence.\u00a0<\/p>\n So why aren\u2019t there better trials for nutraceuticals? I recently tried to design one. A supplement company approached me wanting a publication-quality, randomized controlled trial (RCT) for a promising botanical extract. It also insisted on a compressed budget, a strict limit on participants, and a long wish list of secondary endpoints, including biomarkers and functional assessments. As the design evolved, it became clear that having it all would require both critical design compromises and slashing my investigator fee to something resembling minimum wage.<\/p>\n That experience painted a bigger picture: The nutraceutical sector faces structural barriers that make rigorous research far harder than most stakeholders appreciate. Through this project, I observed five recurring tensions and reflected on what could be a constructive path forward.<\/p>\n Tension 1: Public demand for evidence vs. a system that discourages it<\/p>\n \t\t\t \t\t\t\t In pharmaceuticals, patent exclusivity helps justify the expense of clinical trials. Botanical supplements rarely have this. Products derived from nature, such as turmeric, ashwagandha, and elderberry, are difficult to patent in ways that block competitors. If one company spends $300,000 proving its product supports sleep or immune function, every other brand using the same ingredient benefits for free. From a business standpoint, investing in trials is hard to justify.<\/p>\n Further compounding the issue is the astronomical cost of investigational product of research, driven upward over decades by escalating evidentiary standards, increasingly complex trial designs, and entrenched operational inefficiencies.\u00a0<\/p>\n The result is a contemporary research landscape where large biopharmaceutical companies with big budgets can afford full clinical development, while most nutraceutical firms are effectively priced out of conducting rigorous clinical trials.\u00a0<\/p>\n Tension 2: Realistic costs vs. design quality<\/p>\n Many consumer product companies assume running a clinical trial means recruiting a handful of volunteers, collecting some surveys, and comparing results. But credible trials require validated outcomes, safety monitoring, trained staff, participant support, statistical expertise, and ethics review. These pieces add up quickly. Even small randomized controlled trials can easily exceed $150,000, a number that can feel shockingly high to a nutraceutical sponsor. When money is tight, the first thing to shrink is sample size or follow-up duration. But a small sample can only detect large effects, and short trials are unlikely to demonstrate benefit for natural compounds with gradual effects. Underpowered studies miss signals that matter. The product may work; the study simply can\u2019t show it.<\/p>\n Many manufacturers, including companies that make nutraceuticals, are also embracing decentralized trials (studies conducted in home or community settings using apps and wearable devices) for cost savings purposes, assuming they are cheaper just because there are no research sites.<\/p>\n But in reality, costs don\u2019t disappear \u2014 they shift. When a clinical trial takes place on-site, research staff supervise assessments to ensure consistency and correct conduct. Without sites, every participant becomes a \u201cmicro-site,\u201d requiring an extra layer of training and instruction, equipment troubleshooting, and adherence monitoring from a central research team. Measurement variability increases across living rooms, backyards, and parks, and protecting data quality requires follow-up from investigators.<\/p>\n Decentralized trials bring many benefits, such as increased access, easier participation, and ecological validity, but they don\u2019t eliminate the workload or expertise required to run a rigorous study.<\/p>\n Tension 3: Strength of the research question vs. regulatory limitations<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/02\/GettyImages-2152881541-768x432.jpg\")
\t\t<\/p>\n![\"\"\/](\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/home\/statplus.svg\")
\n\t\t\t\tSTAT Plus: Why Silicon Valley should demand clinical trials for its medical AI<\/a><\/p>\n
![\"\"](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/02\/AdobeStock_334807084-768x432.jpeg\")
\t\t<\/p>\n